Drug Profile
Paclitaxel-hyaluronic acid conjugate - Fidia Farmaceutici
Alternative Names: HA-paclitaxel bioconjugate; Hyaluronic acid-paclitaxel; Oncofid-P; Oncofid®P-B; Paclitaxel-hyaluronic acidLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Fidia Farmaceutici
- Class Antineoplastics; Drug conjugates; Glycosaminoglycans; Paclitaxels; Taxanes
- Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant-mesothelioma
- No development reported Bladder cancer
Most Recent Events
- 24 Sep 2021 No development reported - Phase-II for Bladder cancer in Germany (Intravesicular)
- 24 Sep 2021 No development reported - Phase-II for Bladder cancer in Italy (Intravesicular)
- 24 Sep 2021 No development reported - Phase-II for Bladder cancer in Spain (Intravesicular)